Copyright © 2003 by the European Society of Cardiology.
Clinical research
Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation
Results of a prospective and controlled study
a Division of Cardiology and Cardiovascular Surgery, Institute of Medicine, Chung-Shan Medical University Hospital, Taichung, Taiwan
b National Yang-Ming University, School of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
* Correspondence to: Kwo-Chang Ueng, MD, Division of Cardiology, Chung-Shan Medical University Hospital, Taichung, 110, Sec. 1, Chien-Kuo N. Rd., Taichung, Taiwan. Tel: 886-4-2253-2603; Fax: 886-4-2252-3626
E-mail address: ueng.kc{at}msa.hinet.net
Received 28 April 2003; revised 22 July 2003; accepted 14 August 2003
Abstract
Aims This study aimed to assess whether enalapril could improve cardioversion outcome and facilitate sinus rhythm maintenance after conversion of chronic atrial fibrillation (AF).
Methods and results Patients with chronic AF for more than 3 months were assigned to receive either amiodarone (200mg orally 3 times a day; group I: n=75) or the same dosage of amiodarone plus enalapril (10mg twice a day; group II: n=70) 4 weeks before scheduled external cardioversion. The end-point was the time to first recurrence of AF. In 125 patients (86.2%), AF was converted to sinus rhythm. Group II had a trend to a trend to a lower rate of immediate recurrence of AF than group I did (4.3% vs 14.7%, P=0.067). Kaplan–Meier analysis demonstrated a higher probability of group II remaining in sinus rhythm at 4 weeks (84.3% vs 61.3%, P=0.002) and at the median follow-up period of 270 days (74.3% vs 57.3%, P=0.021) than in group II.
Conclusion The addition of enalapril to amiodarone decreased the rate of immediate and subacute arrhythmia recurrences and facilitated subsequent long-term maintenance of sinus rhythm after cardioversion of persistent AF.
Key Words: Atrial fibrillation • Remodelling • Angiotensin-convertingenzyme inhibitor
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy?
- Hein Heidbüchel
EHJ 2003 24: 2077-2078.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  S. K. Kim, H.-N. Pak, J. H. Park, K. J. Ko, J. S. Lee, J. I. Choi, D. H. Choi, and Y.-H. Kim Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion Europace, December 1, 2009; 11(12): 1632 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hegbom, A. Tveit, I. Grundvold, H. Arnesen, and P. Smith Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation Europace, October 1, 2009; 11(10): 1301 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ozben, M. Sumerkan, A. M. Tanrikulu, N. Papila-Topal, A. S. Fak, and A. Toprak Perindopril decreases P wave dispersion in patients with stage 1 hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 85 - 90. [Abstract] [PDF]
|
|
|
|
 |
|
 D. von Lewinski, J. Kockskamper, S.-U. Rubertus, D. Zhu, J. D. Schmitto, F. A. Schondube, G. Hasenfuss, and B. Pieske Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium Eur J Heart Fail, December 1, 2008; 10(12): 1172 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bollmann, A. Tveit, D. Husser, M. Stridh, L. Sornmo, P. Smith, and S. B. Olsson Fibrillatory rate response to candesartan in persistent atrial fibrillation Europace, October 1, 2008; 10(10): 1138 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dorian and B. N. Singh Upstream therapies to prevent atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H11 - H31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Serra and M. Bendersky Review: Atrial fibrillation and renin-angiotensin system Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 215 - 223. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Soran, N. Younis, P. Currie, J. Silas, I.R. Jones, and G. Gill Influence of diabetes on the maintenance of sinus rhythm after a successful direct current cardioversion in patients with atrial fibrillation QJM, March 1, 2008; 101(3): 181 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-T. Tsai, L.-P. Lai, K.-T. Kuo, J.-J. Hwang, C.-S. Hsieh, K.-L. Hsu, C.-D. Tseng, Y.-Z. Tseng, F.-T. Chiang, and J.-L. Lin Angiotensin II Activates Signal Transducer and Activators of Transcription 3 via Rac1 in Atrial Myocytes and Fibroblasts: Implication for the Therapeutic Effect of Statin in Atrial Structural Remodeling Circulation, January 22, 2008; 117(3): 344 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. Issac, H. Dokainish, and N. M. Lakkis Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2021 - 2028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al. Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) Eur. Heart J., November 2, 2007; 28(22): 2803 - 2817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-R. Neuberger, C. Mewis, D. J. van Veldhuisen, U. Schotten, I. C. van Gelder, M. A. Allessie, and M. Bohm Management of atrial fibrillation in patients with heart failure Eur. Heart J., November 1, 2007; 28(21): 2568 - 2577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association Europace, November 1, 2007; 9(11): 1006 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Platonov Interatrial conduction in the mechanisms of atrial fibrillation: from anatomy to cardiac signals and new treatment modalities Europace, November 1, 2007; 9(suppl_6): vi10 - vi16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif and M. Talajic Perindopril and prevention of atrial fibrillation Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E25 - E29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]
|
|
|
|
|
|
Y. Yin, D. Dalal, Z. Liu, J. Wu, D. Liu, X. Lan, Y. Dai, L. Su, Z. Ling, Q. She, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation Eur. Heart J., August 1, 2006; 27(15): 1841 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Ehrlich, S. H. Hohnloser, and S. Nattel Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence Eur. Heart J., March 1, 2006; 27(5): 512 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E.W. Hemels, A. C.P. Wiesfeld, B. Inberg, P. F.H.M. Van Dessel, W. Nieuwland, E. S. Tan, H. Mulder, D. J. Van Veldhuisen, and I. C. Van Gelder Right atrial overdrive pacing for prevention of symptomatic refractory atrial fibrillation. Europace, February 1, 2006; 8(2): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Boos, R. A. Anderson, and G. Y.H. Lip Is atrial fibrillation an inflammatory disorder? Eur. Heart J., January 2, 2006; 27(2): 136 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Ellinor, A. F. Low, and C. A. MacRae Reduced apelin levels in lone atrial fibrillation Eur. Heart J., January 2, 2006; 27(2): 222 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Kalus, C. I. Coleman, and C. M. White The Impact of Suppressing the Renin-Angiotensin System on Atrial Fibrillation J. Clin. Pharmacol., January 1, 2006; 46(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D.M. Engelmann and J. H. Svendsen Inflammation in the genesis and perpetuation of atrial fibrillation Eur. Heart J., October 2, 2005; 26(20): 2083 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Healey, A. Baranchuk, E. Crystal, C. A. Morillo, M. Garfinkle, S. Yusuf, and S. J. Connolly Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1832 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Bourassa Angiotensin II inhibition and prevention of atrial fibrillation and stroke J. Am. Coll. Cardiol., March 1, 2005; 45(5): 720 - 721. [Full Text] [PDF]
|
|
|
|
 |
|
 P J B Hubner, S Gupta, and I McClellan Simplified cardioversion service with intravenous midazolam Heart, December 1, 2004; 90(12): 1447 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J Boos Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation Eur. Heart J., October 1, 2004; 25(19): 1761 - 1761. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy? Can. Med. Assoc. J., September 28, 2004; 171(7): 752 - 753. [Full Text] [PDF]
|
|
|
|
|
|
A. H Madrid, I. M. Marin, C. Escobar Cervantes, E. Bernal Morell, J. Escudero Estevez, G. Moreno, J. Rondon Parajon, Jian Peng, L. Limon, S. Nannini, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 114 - 120. [Abstract] [PDF]
|
|
|
|
|
|
P. L. L'Allier, A. Ducharme, P.-F. Keller, H. Yu, M.-C. Guertin, and J.-C. Tardif Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation J. Am. Coll. Cardiol., July 7, 2004; 44(1): 159 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel Defining "Culprit Mechanisms" in Arrhythmogenic Cardiac Remodeling Circ. Res., June 11, 2004; 94(11): 1403 - 1405. [Full Text] [PDF]
|
|
|
|
|
|
P. Korantzopoulos, T. Kolettis, E. Kountouris, and K. Siogas Atrial remodeling in persistent atrial fibrillation: the potential role of aldosterone Eur. Heart J., June 2, 2004; 25(12): 1086 - 1086. [Full Text] [PDF]
|
|
|
|
|
|
K.-C. Ueng and S.-A. Chen Atrial remodelling in persistent atrial fibrillation: the potential role of aldosterone: Reply Eur. Heart J., June 2, 2004; 25(12): 1087 - 1087. [Full Text] [PDF]
|
|
|
|
|
|
H. Heidbuchel A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy? Eur. Heart J., December 1, 2003; 24(23): 2077 - 2078. [Full Text] [PDF]
|
|
|
|
|
|
I. Savelieva and A. John Camm Atrial fibrillation and heart failure: natural history and pharmacological treatment Europace, January 1, 2003; 5(s1): S5 - S19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Santini and R. Ricci Atrial fibrillation and heart failure Europace, January 1, 2003; 5(s1): S55 - S59. [Full Text] [PDF]
|
|